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Abstract A single nucleotide polymorphism (SNP) in
KIF6, a member of the KIF9 family of kinesins, is associ-
ated with diVerential coronary event reduction from statin
therapy in four randomized controlled trials; this SNP
(rs20455) is also associated with the risk for coronary heart
disease (CHD) in multiple prospective studies. We investi-
gated whether other common SNPs in the KIF6 region were
associated with event reduction from statin therapy. Of the
170 SNPs in the KIF6 region investigated in the Choles-
terol and Recurrent Events trial (CARE), 28 were associ-
ated with diVerential event reduction from statin therapy
(Pinteraction < 0.1 in Caucasians, adjusted for age and sex)
and were further investigated in the Pravastatin or Atorva-
statin Evaluation and Infection Therapy-Thrombolysis In
Myocardial Infarction 22 (PROVE IT-TIMI22) and West
of Scotland Coronary Prevention Study (WOSCOPS).
These analyses revealed that two SNPs (rs9462535 and
rs9471077), in addition to rs20455, were associated with
event reduction from statin therapy (Pinteraction < 0.1 in each
of the three studies). The relative risk reduction ranged
from 37 to 50% (P < 0.01) in carriers of the minor alleles of
these SNPs and from ¡4 to 13% (P > 0.4) in non-carriers.
These three SNPs are in high linkage disequilibrium with
one another (r2 > 0.84). Functional studies of these variants
may help to understand the role of KIF6 in the pathogenesis
of CHD and diVerential response to statin therapy.
Introduction
The risk for coronary heart disease (CHD) varies between
individuals and can be ameliorated by lifestyle changes and
medications such as statins. Although statins have been
shown to be highly eVective in reducing CHD events in
randomized controlled trials, individual response to statin
therapy varies (reviewed in Mangravite et al. 2006;
Schmitz and Langmann 2006), a variability thought to be
partly due to genetic factors.
Recently, a common single nucleotide polymorphism
(SNP) in KIF6, a member of the KIF9 family of kinesins,
has been reported to be associated with CHD risk and
diVerential reduction of coronary events from statin therapy
(Bare et al. 2007; Iakoubova et al. 2008a, b, 2009; ShiVman
et al. 2008a, b); this SNP (rs20455) encodes the missense
polymorphism KIF6 Trp719Arg. In a meta-analysis of
seven prospective studies, carriers of the 719Arg variant
had over 20% increased risk of CHD, compared with non-
carriers (P = 1.02 £ 10¡6) (Li et al. 2010). This increased
risk was independent of traditional risk factors including
age, blood pressure, diabetes, smoking, low-density lipo-
protein cholesterol (LDL-C) or high-density lipoprotein
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18 Hum Genet (2011) 129:17–23cholesterol (HDL-C). However, an association between the
KIF6 Trp719Arg polymorphism and CHD was not
observed in two case–control studies (Stewart et al. 2009;
Wellcome Trust Case Control Consortium 2007), possibly
due to statin use.
The 719Arg variant was also associated with greater
reduction of coronary events from both pravastatin (a
hydrophilic statin) and atorvastatin (a lipophilic statin) ther-
apy. In retrospective genetic analyses of four prospective
clinical trials, the Cholesterol and Recurrent Events trial
(CARE) (Sacks et al. 1996), the West of Scotland Coronary
Prevention Study (WOSCOPS) (Shepherd et al. 1995),
Pravastatin or Atorvastatin Evaluation and Infection Ther-
apy-Thrombolysis In Myocardial Infarction 22 (PROVE
IT-TIMI22) (Cannon et al. 2004), and the PROspective
Study of Pravastatin in the Elderly at Risk (PROSPER),
carriers of the 719Arg variant (»60% of people of Euro-
pean ancestry) had substantial and signiWcant reduction of
CHD events from statin therapy, whereas non-carriers did
not (Iakoubova et al. 2008a, b, 2009).
Here we have conducted a Wne mapping study to deter-
mine (1) whether other SNPs or haplotypes in the KIF6
region account for the association of rs20455 (Trp719Arg)
with diVerential coronary event reduction from statin ther-
apy and (2) whether other variants in the KIF6 region are
independently associated with diVerential reduction of
events from statin therapy.
Methods
Study population
The populations in this genetic study were derived from
three prospective double blind, randomized clinical tri-
als that evaluated the eVect of statin therapy on coronary
events: CARE, PROVE IT-TIMI22, and WOSCOPS.
CARE evaluated the eVect of 40 mg/day pravastatin,
compared with placebo, on the reduction of fatal CHD
and nonfatal myocardial infarction (MI) in men and
women with a prior MI and LDL-C levels between 115
and 174 mg/dL (average age of 59 years old); WOSC-
OPS evaluated the eVect of 40 mg/day pravastatin, com-
pared with placebo, on the reduction of fatal and
nonfatal CHD in men with LDL-C levels between 174
and 232 mg/dL (age ranged from 45 to 64 years old) and
no history of MI; PROVE IT-TIMI 22 evaluated the
eVect of intensive statin therapy (80 mg/day atorva-
statin), compared with moderate statin therapy (40 mg/
day pravastatin), on fatal and nonfatal cardiovascular
events in men and women after acute coronary syn-
dromes (average age of 58 years old). The average fol-
low-up period was 5, 2 and 4.9 years for the CARE,
PROVE IT-TIMI 22 and WOSCOPS trials, respectively.
The current genetic analyses were performed in those
patients whose DNA was available: 2,913 in CARE,
1,817 in PROVE IT-TIMI22, and 1,570 in WOSCOPS;
note that for WOSCOPS we obtained access to a previ-
ously described nested case–control study that included
all cases, who had CHD events and age- and smoking
status-matched controls who did not have events during
the WOSCOPS trial (Packard et al. 2000). This study
was limited to Caucasian patients to avoid complications
arising from potential diVerences in linkage disequili-
brium (LD) structure in diVerent populations and because
each trial enrolled only about 10% or fewer non-Cauca-
sian patients. Characteristics of the patients included in
this genetic study can be found in Supplementary
Table 1.
The endpoints were either the primary endpoint of the
original clinical trials (for CARE and PROVE IT-
TIMI22) or that of the previously reported nested case–
control study of WOSCOPS (Packard et al. 2000). For
CARE, the endpoint was fatal coronary event or nonfatal
MI (ShiVman et al. 2010); for PROVE IT-TIMI22, the
endpoint was death from any cause or major cardiovascu-
lar events including MI, revascularization, unstable
angina requiring hospitalization and stroke (Cannon et al.
2004); and for WOSCOPS, the endpoint was CHD death,
nonfatal MI, and revascularization (Shepherd et al. 1995).
Genotypes were determined in a core facility by either
allele-speciWc real-time PCR (Germer et al. 2000) or multi-
plexed PCR of genomic DNA followed by multiplexed
allele detection (Iannone et al. 2000). Genotyping was
carried out in plates with randomly arrayed samples, and
genotype calls were made without the knowledge of the
sample event status.
SNP selection
The interrogated region on chromosome 6 spanned from
39,392,028 to 39,809,728 bp, corresponding to the posi-
tions of rs1535500 and rs215497. This region includes the
entire KIF6 gene plus 8.6 kbp upstream and 18.8 kbp
downstream of the KIF6 gene (Fig. 1). A total of 178 SNPs
in this KIF6 region were genotyped in CARE, including
rs20455 and 26 other SNPs whose association with risk of
CHD had been investigated previously (Iakoubova et al.
2008b). Of the 178 SNPs included in this study, the geno-
type distributions of Wve SNPs did not meet Hardy–Wein-
berg expectations (P < 0.001) and three SNPs had an allele
frequency less than 2%; the remaining 170 SNPs were ana-
lyzed for association with diVerential coronary event reduc-
tion from statin therapy. All 450 SNPs in the KIF6 region
in the HapMap dataset (de Bakker et al. 2005) with an
allele frequency greater than 2% were either included in123
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SNPs.
One objective of the current study was to determine
the presence of a SNP in the KIF6 region that could
explain the association of KIF6 Trp719Arg SNP with
diVerential reduction of coronary events from statin.
Therefore, to avoid missing such a hypothetical ‘causa-
tive’ SNP that, by chance, had a weak association in one
of the studies we set a relaxed threshold (Pinteraction < 0.1)
for advancing SNPs from one study to the next. There-
fore, the Xow of the study was as following: SNPs were
Wrst tested in CARE, and those that were associated with
diVerential reduction of events from statin therapy
(Pinteraction < 0.1) were then analyzed in PROVE IT-
TIMI22. SNPs that were associated with statin response
in PROVE IT-TIMI22 (Pinteraction < 0.1 and hazard ratio
in the same direction as in CARE) were further analyzed in
WOSCOPS. We adopted this sequence of analysis partly
because only a limited amount of DNA was available
from patients in the WOSCOPS study.
Statistical analyses
Genotype distribution in the individual studies was tested
for deviation from Hardy–Weinberg equilibrium (HWE) by
an exact test.
For each SNP, likelihood ratio tests comparing Cox
(CARE and PROVE IT-TIMI22) or logistic regression
models (WOSCOPS) with and without an interaction term
between genotype and statin therapy were used to evaluate
heterogeneity (measured by Pinteraction) of event reduction
from statin therapy. Additive, dominant, and recessive
models for each SNP were coded using the major allele
(deWned in CARE) as the reference allele so that the direc-
tion of estimated parameters would be consistently mea-
sured across all three studies.
The LD measure r2 was calculated from unphased data
with the LDMAX program in the GOLD package (Abeca-
sis and Cookson 2000). Haplotype frequencies were esti-
mated from the genotype data and, using the posterior
probabilities of possible haplotype pairs for each subject,
Fig. 1 Linkage disequilibrium and association with statin therapy in
CARE. Gene and SNP locations and SNP to SNP LD in the HapMap
dataset (in D ranging from 1 in red to 0 in white) in the KIF6 region
are shown in the lower part of the Wgure. The LD block containing
rs20455 is indicated with a green bar. LD between rs20455 and other
genotyped SNPs in CARE is shown in the middle part of the Wgure.
Nucleotide position on the chromosome is indicated below the x axis
in kilobases. Association between SNP and event reduction in CARE
(dominant model Pinteraction) is presented in the top panel123
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from statin therapy using logistic regression as imple-
mented in the R package haplo.stats (Lake et al. 2003;
Schaid et al. 2002). A sliding window was used to select
haplotypes consisting of three or Wve adjacent SNPs.
Results
To Wne map the KIF6 region, we analyzed 170 SNPs to
determine whether reduction of fatal CHD or conWrmed
nonfatal MI events from statin therapy in CARE diVered
between genotype-deWned subgroups as assessed by
the interaction between genotype and treatment group
(Pinteraction, see “Methods”). We found that 44 SNPs met
the Pinteraction threshold of <0.1 (Supplementary Tables 2,
3 and 4). Of the 17 SNPs associated with diVerential
reduction of events from statin therapy in the recessive
model, 16 SNPs were excluded from further analysis,
because for each of these SNPs, fewer than 4% of the
patients were minor homozygotes and there were very
few events (<10) among the minor homozygotes. The
remaining 28 SNPs (including rs20455) associated with
diVerential reduction of events from statin therapy
included 12 SNPs that were in LD with rs20455 and
clustered in a 53 kbp region (Fig. 1, indicated by a green
bar above the LD map).
We then analyzed these 28 SNPs in the PROVE IT-
TIMI22 cohort using the genetic model for each SNP that
was most signiWcant in the CARE analysis. Six SNPs were
associated with diVerential event reduction from statin ther-
apy (Pinteraction < 0.1) in PROVE IT-TIMI22, and event
reduction from statin therapy was greatest in the same
genotype for all six SNPs: 2 in the additive model and 4 in
the dominant model (Supplementary Tables 5 and 6). Fur-
ther analyses of these six SNPs in the WOSCOPS study
showed that three SNPs (rs20455, rs9462535 and
rs9471077) were diVerentially associated with coronary
event reduction by statin use (Pinteraction < 0.1, dominant
model; Table 1; Fig. 2). These three SNPs were in high LD
with each other (r2 = 0.84–0.98) (Supplementary Table 7).
We next carried out haplotype analyses in CARE in the
53 kbp region of high LD surrounding rs20455 (green bar
in Fig. 1) using a sliding window approach (Schaid et al.
2002). Results of haplotypes comprising three SNPs along
with the results of the most signiWcant individual SNP in a
given haplotype are shown in Supplemental Fig. 1. In
CARE, only the haplotypes based on rs45460596,
rs9394585 and rs9357303 were more signiWcantly associ-
ated with event reduction than the best of the three SNPs
Table 1 Association of the three SNPs in the KIF6 region with diVerential reduction of coronary events from statin therapy in CARE, PROVE
IT-TIMI 22 and WOSCOPS studies
* Drug was Pravastatin in CARE and WOSCPS and Atorvastatin in PROVE IT-TIMI22; Comparator was placebo in CARE and WOSCOPS and pravastatin in
PROVE IT-TIMI22
** Model 1 for CARE and PROVE IT-TIMI22 is adjusted for age and sex; WOSCOPS is unadjusted
*** Model 2 is adjusted for age, smoking, hypertension, diabetes, high-density cholestrol (HDL-C) level, and non-HDL-C level; additional adjustments include sex
and body mas index for CARE, sex and treatment for gatiXoxacin for PROVE IT-TIMI22
SNP type Study Genotype Drug* Comparator* Model 1** Model 2***
Events Total Events Total HR or OR (95% CI) Presponse Pinteraction HR or OR (95% CI) Presponse Pinteraction
rs20455
Trp719Arg
CARE CT + CC 76 810 111 791 0.65 (0.49–0.88) 0.0045 0.0975 0.67 (0.50–0.90) 0.0074 0.1708
TT 52 554 51 542 0.98 (0.67–1.45) 0.9241 0.93 (0.63–1.38) 0.6749
PROVE IT-TIMI22 CT + CC 90 533 142 532 0.60 (0.46–0.78) 0.0001 0.0206 0.62 (0.48–0.80) 0.0003 0.0292
TT 87 375 91 375 0.94 (0.70–1.26) 0.6802 0.96 (0.70–1.32) 0.8226
WOSCOPS CT + CC 108 330 172 263 0.50 (0.37–0.67) <0.0001 0.0063 0.50 (0.37–0.68) <0.0001 0.0116
TT 81 213 104 256 0.94 (0.66–1.32) 0.7055 0.89 (0.63–1.26) 0.5126
rs9462535
Intronic
CARE AC + AA 78 873 110 832 0.66 (0.50–0.89) 0.0056 0.0634 0.67 (0.50–0.90) 0.0084 0.1171
CC 55 535 53 538 1.04 (0.71–1.52) 0.8333 0.99(0.67–1.44) 0.9383
PROVE IT-TIMI22 AC + AA 97 568 149 558 0.61 (0.47–0.79) 0.0001 0.0258 0.61 (0.47–0.79) 0.0002 0.0273
CC 80 340 85 349 0.95 (0.70–1.30) 0.7603 0.95 (0.69–1.29) 0.7327
WOSCOPS AC + CC 113 335 184 279 0.51 (0.39–0.68) <0.0001 0.0144 0.51 (0.38–0.68) <0.0001 0.0188
CC 75 197 96 228 0.90 (0.63–1.29) 0.5805 0.87 (0.60–1.25) 0.4538
rs9471077
Intronic
CARE CT + CC 70 813 106 789 0.63 (0.47–0.85) 0.0026 0.0258 0.64 (0.47–0.87) 0.0042 0.0517
TT 52 488 47 488 1.10 (0.74–1.64) 0.6309 1.04 (0.70–1.55) 0.8401
PROVE IT-TIMI22 CT + CC 99 569 149 560 0.62 (0.48–0.80) 0.0002 0.0320 0.59 (0.45–0.77) 0.0001 0.0816
TT 78 335 83 344 0.96 (0.70–1.31) 0.7984 0.94 (0.70–1.28) 0.7081
WOSCOPS CT + CC 113 340 175 284 0.54 (0.41–0.72) <0.0001 0.0146 0.54 (0.40–0.72) <0.0001 0.0178
TT 76 196 94 231 0.95 (0.67–1.36) 0.7914 0.92 (0.64–1.32) 0.6365123
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PROVE IT-TIMI22 these haplotypes were not associated
with event reduction (dominant haplotype Pinteraction =
0.55). Testing of haplotypes consisting of Wve adjacent
SNPs did not reveal any haplotype that was more signiW-
cant than the corresponding individual SNPs (data not
shown).
We also carried out a haplotype analysis in CARE of the
three SNPs (rs9471077, rs9462535, and rs20455) that were
associated with event reduction in all three studies. Two
common (>5%) haplotypes were observed, which corre-
sponded to KIF6 710Arg carriers and non-carriers (data not
shown). Due to the high LD between these three SNPs, we
were unable to diVerentiate the eVects of one SNP from
another despite exploring both pairwise adjustment and
stepwise regression analyses. For example, there were only
six events each in placebo and statin-treated subjects
among the combinations where the genotypes are discor-
dant (data not shown).
Since rs20455 had also been reported to be associated
with CHD, we analyzed association of the two other SNPs
(rs9462535 and rs9471077) that were consistently associ-
ated with event reduction in CARE and WOSCOPS. We
found that they were also associated with CHD (Table 2).
Discussion
This study was designed to investigate whether (1) the pre-
viously reported association of rs20455 (Trp719Arg) with
coronary event reduction from statin therapy could be bet-
ter explained by another SNP in the KIF6 region and (2)
other SNPs in the KIF6 region were associated with coro-
nary event reduction from statin therapy independently of
rs20455. We found that two additional SNPs in strong LD
with rs20455 were consistently associated (Pinteraction < 0.1)
with diVerential reduction of clinical events from statin
therapy in the CARE, WOSCOPS, and PROVE IT-TIMI22
studies. These two SNPs are located in introns, while
rs20455 is a missense polymorphism in the KIF6 gene.
Previously, we have tested 27 SNPs, including rs20455,
in a 95.5 kbp portion of the KIF6 region (from position
39,347,330 to position 39,442,863 on chromosome 6) for
association with CHD in the placebo arms of the CARE
and WOSCOPS studies (Iakoubova et al. 2008b). This
study expands the interrogated region and focuses on
diVerential event reduction from statin therapy, an eVect of
particular clinical interest. The three SNPs that we found
to be associated with diVerential response to statin therapy
are highly correlated and thus indistinguishable from each
Fig. 2 EVect of statin therapy 
on coronary events stratiWed by 
the genotype of three SNPs in 
CARE, PROVE IT-TIMI22 and 
WOSCOPS studies. The hazard 
ratios or odds ratios were calcu-
lated for Model 2 in Table 1
Table 2 Association of the three SNPs in the KIF6 region and coronary events in the placebo groups of CARE and WOSCOPS
* Model 1 for CARE is adjusted for age and sex; WOSCOPS is unadjusted
** Model 2 is adjusted for age, smoking, hypertension, diabetes, body mass index, high density cholesterol (HDL-C) level, and non-HDL-C level;
CARE is also adjusted for sex
SNP Genotype Study Model 1* Model 2**
HR or OR (95% CI) P HR or OR (95% CI) P
rs20455 CT + CC versus TT CARE 1.54 (1.10–2.14) 0.0112 1.48 (1.06–2.06) 0.0215
WOSCOPS 1.61 (1.19–2.17) 0.0017 1.55 (1.15–2.10) 0.0045
rs9462535 AC + AA versus CC CARE 1.38 (1.00–1.92) 0.0530 1.32 (0.95–1.84) 0.0944
WOSCOPS 1.57 (1.16–2.12) 0.0036 1.53 (1.12–2.08) 0.0069
rs9471077 CT + CC versus TT CARE 1.44 (1.02–2.03) 0.0376 1.38 (0.98–1.95) 0.0678
WOSCOPS 1.51 (1.12–2.05) 0.0077 1.46 (1.07–1.99) 0.0160123
22 Hum Genet (2011) 129:17–23other in this association. However, the possibility that the
719Trp versus 719Arg variation has functional conse-
quences is supported by the BLOSUM62 score of ¡3 for
this variation. The BLOSUM62 score is the log odds for
amino acid substitutions in conserved protein blocks
(HenikoV and HenikoV 1992), and a score of ¡3 indicates
a less likely substitution. As the Trp719Arg substitution is
near the putative cargo-binding tail domain of the kinesin,
it would be interesting to determine whether the amino
acid change aVects the binding of cargo molecules by the
KIF6 protein.
One limitation of our study is that we were unable to
deWne the causal variant with certainty. Strategies to
identify causal variants include performing genetic asso-
ciation studies in a diVerent population that might have a
distinct LD structure for these tightly linked SNPs from
the initial studies. The CARE and PROVE IT-TIMI22
cohorts had small numbers of non-Caucasian partici-
pants; therefore, the power to conduct an association
study in the non-Caucasian population is limited.
Another limitation is that PROVE IT-TIMI22 may not
be comparable to CARE and WOSCOPS—the former
tested intensive statin therapy compared with moderate
statin therapy, while the latter tested 40 mg/day prava-
statin compared with placebo. Therefore, by including
PROVE IT-TIMI22, we may have missed the SNPs that
are capable of predicting event reduction response to
pravastatin compared with placebo but not intensive sta-
tin therapy compared with moderate statin therapy. Such
SNPs may be independent from rs20455, which predicts
diVerential event reduction from both 40 mg/day prava-
statin compared with placebo and intensive statin ther-
apy compared with moderate statin therapy. In addition,
PROVE IT-TIMI22 primary endpoint included a small
fraction (5.2% of primary events) of death from presum-
ably non-cardiovascular events, while the CARE end-
point and the WOSCOPS case deWnition did not include
non-cardiovascular death.
In conclusion, we have identiWed three highly linked
SNPs in the KIF6 region that predict diVerential reduc-
tion of coronary events from statin therapy. Functional
characterization of these variants is warranted and could
help to explain the role of KIF6 in the pathogenesis of
CHD and the variable event reduction in response to sta-
tin therapy.
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